INTEGRIS-PSC Enrollment Complete
The INTEGRIS-PSC clinical trial is studying PLN-74809, an oral investigational medicine designed to directly target the development of liver fibrosis (when tissue becomes damaged and scarred, affecting normal function of the organ) in patients with primary sclerosing cholangitis, or PSC. The medicine has been tested in over 600 healthy volunteers and patients and was well tolerated. It is taken orally once per day for 12 weeks.
By stopping the cellular process that causes fibrosis, bexotegrast (PLN-74809) may have the potential to slow or stop the progressive decline in liver function that happens with PSC. This study will help establish the bexotegrast (PLN-74809) safety profile and provide early insights on whether it affects the progression of the disease.
Enrollment in the INTEGRIS-PSC trial is complete.
Pliant would like to thank our INTEGRIS-PSC clinical sites, investigators and study teams for their assistance in the successful execution of this study.
A special thanks to the clinical participants and their families and support networks for helping us advance this important program.